Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity

D. Matino, D. Lillicrap, J. Astermark, G. Dolan, C. Kessler, T. Lambert, M. Makris, J. O'Donnell, S. Pipe, E. Santagostino, J. M. Saint-Remy, W. Schramm, A. Iorio

Research output: Contribution to journalArticle

Abstract

The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalHaemophilia
Volume20
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Blood Coagulation Factors
Factor VIII
Hemophilia A
Neutralizing Antibodies
Documentation
Incidence

Keywords

  • Clotting factor concentrates
  • Haemophilia
  • Immunogenicity
  • Inhibitors

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Matino, D., Lillicrap, D., Astermark, J., Dolan, G., Kessler, C., Lambert, T., ... Iorio, A. (2014). Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity. Haemophilia, 20(2), 200-206. https://doi.org/10.1111/hae.12283

Switching clotting factor concentrates : Considerations in estimating the risk of immunogenicity. / Matino, D.; Lillicrap, D.; Astermark, J.; Dolan, G.; Kessler, C.; Lambert, T.; Makris, M.; O'Donnell, J.; Pipe, S.; Santagostino, E.; Saint-Remy, J. M.; Schramm, W.; Iorio, A.

In: Haemophilia, Vol. 20, No. 2, 2014, p. 200-206.

Research output: Contribution to journalArticle

Matino, D, Lillicrap, D, Astermark, J, Dolan, G, Kessler, C, Lambert, T, Makris, M, O'Donnell, J, Pipe, S, Santagostino, E, Saint-Remy, JM, Schramm, W & Iorio, A 2014, 'Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity', Haemophilia, vol. 20, no. 2, pp. 200-206. https://doi.org/10.1111/hae.12283
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T et al. Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity. Haemophilia. 2014;20(2):200-206. https://doi.org/10.1111/hae.12283
Matino, D. ; Lillicrap, D. ; Astermark, J. ; Dolan, G. ; Kessler, C. ; Lambert, T. ; Makris, M. ; O'Donnell, J. ; Pipe, S. ; Santagostino, E. ; Saint-Remy, J. M. ; Schramm, W. ; Iorio, A. / Switching clotting factor concentrates : Considerations in estimating the risk of immunogenicity. In: Haemophilia. 2014 ; Vol. 20, No. 2. pp. 200-206.
@article{d6dbf0855c3246c4875d655b44a0d897,
title = "Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity",
abstract = "The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.",
keywords = "Clotting factor concentrates, Haemophilia, Immunogenicity, Inhibitors",
author = "D. Matino and D. Lillicrap and J. Astermark and G. Dolan and C. Kessler and T. Lambert and M. Makris and J. O'Donnell and S. Pipe and E. Santagostino and Saint-Remy, {J. M.} and W. Schramm and A. Iorio",
year = "2014",
doi = "10.1111/hae.12283",
language = "English",
volume = "20",
pages = "200--206",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Switching clotting factor concentrates

T2 - Considerations in estimating the risk of immunogenicity

AU - Matino, D.

AU - Lillicrap, D.

AU - Astermark, J.

AU - Dolan, G.

AU - Kessler, C.

AU - Lambert, T.

AU - Makris, M.

AU - O'Donnell, J.

AU - Pipe, S.

AU - Santagostino, E.

AU - Saint-Remy, J. M.

AU - Schramm, W.

AU - Iorio, A.

PY - 2014

Y1 - 2014

N2 - The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.

AB - The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.

KW - Clotting factor concentrates

KW - Haemophilia

KW - Immunogenicity

KW - Inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84894269397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894269397&partnerID=8YFLogxK

U2 - 10.1111/hae.12283

DO - 10.1111/hae.12283

M3 - Article

C2 - 24533949

AN - SCOPUS:84894269397

VL - 20

SP - 200

EP - 206

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -